Search clinical trials for: TAK-438

Total 5493 results

Takeda

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants

Healthy Participants

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic

United States
Takeda
Takeda Development Center Americas, Inc.

Completed

A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery

Postoperative Gastrointestinal Dysfunction

United States, Germany
Neurocrine Biosciences
Takeda

Completed

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

Schizophrenia | Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Completed

TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants

Depressive Disorder

United Kingdom
Millennium Pharmaceuticals, Inc.

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants

Healthy Volunteers

United States
Takeda

Completed

Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants

Schizophrenia

United States
Takeda

Terminated

Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes (GRAND-307)

Type 2 Diabetes Mellitus

Taiwan, China, Korea, Republic of, New Zealand, Australia
Takeda

Withdrawn

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults

Coronavirus Disease
Takeda

Completed

TAK-020 Relative Bioavailability and Food Effect Study in Healthy Participants

Healthy

United Kingdom
Takeda
Takeda Development Center Americas, Inc.

Terminated

A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery

Crohn Disease

United States, Germany, Austria, France, United Kingdom
Neurocrine Biosciences
Takeda

Completed

A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants

Healthy Volunteers

United States
Takeda

Completed

A Study of TAK-079 in People With Generalized Myasthenia Gravis

Myasthenia Gravis

United States, Spain, Canada, Serbia, Italy, Poland
Takeda

Completed

A Study of TAK-105 in Healthy Adults

Healthy Volunteers

United States
Takeda

Completed

Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)

Gastric Ulcers | Duodenal Ulcers

Japan
Takeda

Completed

Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults

Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Completed

A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants

Healthy Volunteers

United States
Takeda

Completed

Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis

Erosive Esophagitis

China, Taiwan, Korea, Republic of, Malaysia
Yale University
First Pavlov State Medical University in St. Petersburg, Russia

Completed

Patient Driven Recovery With Nalmefene and Coaching

Opioid-use Disorder | Harmful; Use, Alcohol

United States
National Cancer Institute (NCI)

Not yet recruiting

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory High Risk Myelodysplastic Syndrome
Neurocrine Biosciences
Takeda

Completed

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants

Healthy

United States
Takeda

Completed

Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)

Healthy Volunteers

Japan
Takeda

Completed

Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)

Gastric Ulcers | Duodenal Ulcers

Japan
Takeda

Completed

TAK-438_110 Drug Interaction With Cytochrome P450 3A4 (CYP3A4) Inhibitor Clarithromycin

Healthy Volunteers
Takeda

Completed

A Study to Evaluate the Bioequivalence (BE) and the Food Effect of TAK-438ASA Tablet

Healthy Volunteers

Japan
Samsung Bioepis Co., Ltd.

Completed

A Phase I Study of SB26 in Healthy Volunteers

Healthy Volunteers

United States
Millennium Pharmaceuticals, Inc.

Terminated

A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)

Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies

United States
Takeda

Completed

TAK-114 Single- and Multiple-Dose Phase 1 Study

Clinical Pharmacology

Japan
Takeda

Completed

Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults

Influenza Infection
Takeda

Completed

Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants

Influenza Infection

Japan
Takeda

Completed

A Study of TAK-227 in Healthy Adults

Healthy Volunteers

United States
Calithera Biosciences, Inc

Terminated

TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

Spain, United States, Italy, Canada, France, United Kingdom
Calithera Biosciences, Inc

Completed

A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies

Advanced Solid Tumor and Lymphoma Malignancies

United States, Spain, Italy, United Kingdom
Calithera Biosciences, Inc

Terminated

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies

Advanced Nonhematological Neoplasms

Korea, Republic of, Japan, Taiwan
Takeda

Withdrawn

Bioavailability and Food Effect Study of Two Formulations of TAK-906

Healthy Volunteers

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

Colorectal Cancer | Esophageal Neoplasms | Metastatic Pancreatic Cancer | Carcinoma, Non-small-cell Lung

United States, Japan
Neurocrine Biosciences
Takeda

Completed

A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation

Healthy Volunteers

United States
Takeda

Completed

A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Single Intravenous (IV) TAK-954

Renal Impairment | Healthy Volunteers

Czechia, Hungary
Takeda

Completed

A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954

Healthy Volunteers | Hepatic Impairment

Czechia, Slovakia
Millennium Pharmaceuticals, Inc.

Completed

A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies

Carcinoma, Basal Cell | Advanced Nonhematologic Malignancies

United States
Takeda

Terminated

Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus
Millennium Pharmaceuticals, Inc.

Completed

Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma

Lymphoma | Advanced Solid Tumors

United States
Takeda

Completed

Study of TAK-672 in Participants With Acquired Hemophilia A

Acquired Hemophilia A

Japan
Takeda

Completed

Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants

Healthy Volunteers

United States
Takeda

Completed

Phase 1, TAK-648, Single-Rising Dose Study

Healthy Volunteers
Takeda

Recruiting

A Study of TAK-279 in Adults With or Without Kidney Problems

Renal Impairment | Healthy Volunteers

United States
Takeda

Active, not recruiting

A Study of TAK-103 in Adult With Solid Tumors

Solid Tumors

Japan
Takeda

Completed

A Study of Different Forms of TAK-994 in Healthy Adults

Healthy Participants

United States
Millennium Pharmaceuticals, Inc.

Completed

A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Myelofibrosis | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Waldenstrom's Macroglobulinemia | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia | Non-Hodgkins Lymphoma | Myeloid Metaplasia | Philadelphia Chromosome-negative CML | Advanced Polycythemia

United States
Takeda

Completed

Open-label Study of TAK-875

Diabetes Mellitus

Japan

3

Subscribe